News

Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy
Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...